|
|
|
| Influence of lipid microsphere alprostadil combined with edaravone onneurological function and serum S100B level of acute ischemic stroke patients |
| AN Zhanjun1,XU Lixia2,and CAO Jiewei1 |
.1.The Second Department of Internal Medicine,Hebei Provincial Corps Hospital, Chinese People’s Armed Police Force, Shijiazhuang 050081, China;
2.Department of Medical Oncology, the Forth Affiliated Hospital of Hebei Medical University, Shijiazhuang 050031, China |
|
|
|
|
Abstract Objective To investigate the influence of lipid microsphere alprostadil combined with edaravone on the neurological function and serum S100B level of patients with acute cerebral infarction.Methods Between June 2014 and June 2016, sixty patients with acute cerebral infarction were enrolled and randomly and equally divided into the combined group (lipid microsphere alprostadil and edaravone) and the control group (edaravone alone). All the patients received brain MRI examinations(DWI) before treatment, and NIHSS and serum S100B tests before treatment as well as at day 3, 7 and 14 during treatment. The changes of NIHSS and serum S100B levels were compared between the two groups at different time points.Results NIHSS and serum S100B levels of the combined group at day 3, 7 and 14 during treatment were significantly lower than those of the control group(P<0.01). There were two cases of disease progression in the control group, but with no cases of adverse reactions. In the combined group, there was one case of progression, two cases of headache, and one patient who appeared red-faced and felt slightly swollen.Conclusions Lipid microsphere alprostadil combined with edaravone can improve clinical efficacy and alleviate brain damage in patients with acute ischemic stroke.
|
|
Received: 03 October 2016
|
|
|
|
|
|
| [1] |
全国第四届脑血管病学术委员会. 各类脑血管疾病诊断要点[J].中华神经科杂志, 1996, 29(6): 379-381.
|
| [2] |
Khoury R, Jung R, Nanda A, et al. Overview of key factors in improving access to acute stroke care [J]. Neurology, 2012, 79(13): 26-34.
|
| [3] |
Wardlaw J M, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke:an updated systematic review and meta-analysis[J]. Lancet, 2012, 379(9834): 2364-2372.
|
| [4] |
Wang Y, Liao X, Zhao X, et al. Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China:analysis of the results from the Chinese National Stroke Registry (CNSR)[J]. Stroke, 2011, 42(6):1658-1664.
|
| [5] |
赵彦超. 前列地尔联合依达拉奉治疗急性脑梗死的疗效观察[J]. 中国实用神经疾病杂志,2015, 18(18):111-113.
|
| [6] |
彭 晓. 依达拉奉联合前列地尔脂微球注射液治疗急性进展性脑梗死患者临床疗效观察[J]. 现代诊断与治疗, 2015, 2(3): 517-518.
|
| [7] |
Shaw G,Marlatt N,Ferguson P,et al.Identification of a dimefic intermediate in the unfolding pathway for the calcium—binding protein S100B[J].Mol Biol,2008,382:1075-1088
|
| [8] |
Guglielmo S,Francesca R,Cataldo A,et al.S100B protein in tissue development,repair and regeneration[J].World J Biol Chem,2013,4(1):1-12.
|
| [9] |
Nguyen D N,huyghens L,wellens F, et al. Serum S100B protein could help to detect cerebral complications associated with extracorporeal membrane oxygenation (ECMO)[J].Neurocritical Care,2014,20(3):367-374.
|
| [10] |
Wadiwala M F,Sonawalla A,Karnal A K.What is the ro1e of free radical scavengers in acute stroke?[J].J Pak Med Assoc, 2012, 62(5):512-513.
|
| [11] |
Ren Y,Wei B,Song X,et al.Edaravone’s free radical scavenging mechanisms of neuroprotection against cerebral ischemia:review of the literature[J].Int J Neurosci, 2015, 125(8):555-565.
|
| [12] |
Li J H, Yang P, Li A L, et al. Cardioprotective effect of liposomal prostaglandin E1 on a porcine model of myocardial infarction reperfusion no-reflow [J]. J Zhejiang Univ Sci B,2011,12(8):638-643.
|
| [13] |
Dong M F,Ma Z S, Ma S J, et al. Effect of prostaglandin E1 on pulmonary arterial hypertension following corrective surgery for congenital heart disease [J]. J Cardiovasc Pharmacol Ther, 2012, 17(17):303-307.
|
| [14] |
Liu H J, Ma J W, Qiao Z Y, et al. Study of molecular mechanism of prostaglandin E1 in inhibiting coronary heart disease[J]. Mol Biol Rep, 2013, 40(12):6701-6708.
|
| [15] |
Liu W J, Ming Q, Shen J Y, et al. Trimetazidine prevention of contrast-induced nephropathy in coronary angiography[J]. Am J Med Sci, 2015, 350(5):398-402.
|
| [16] |
Eyuboglu M.Renin-angiotensin-aldosterone-system blochade and contrast-induced nephropaphy [J]. Int J cardiol, 2015, 202(4):196-203.
|
|
|
|
2017, Vol. 28 
